Request Appointment
160 East 53rd StreetNew York, NY 10022
Overview of Dr. Ku
Dr. Geoffrey Ku is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 15 years. He is one of 507 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2008
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2005
Perelman School of Medicine at the University of PennsylvaniaClass of 2002
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2027
NY State Medical License 2012 - 2027
Clinical Trials
- Durvalumab, an Anti-PDLI Antibody, and Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation Before Surgery for Esophageal Cancer
- Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery Start of enrollment: 2021 Dec 02
- ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2) Start of enrollment: 2021 Sep 15
Roles: Principal Investigator, Contact
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsZanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, sin...Elena Elimova, Jaffer Ajani, Howard Burris, Crystal S Denlinger, Syma Iqbal
The Lancet. Oncology. 2025-07-01 - Esophagectomy may have a role in stage IV esophageal adenocarcinoma.Marisa Sewell, Nicolas Toumbacaris, Kay See Tan, Nadia Bahadur, John Philip
The Journal of Thoracic and Cardiovascular Surgery. 2025-07-01 - A First-in-Human Study of Givastomig, a CLDN18.2 and 4-1BB Bispecific Antibody, as Monotherapy in Patients with CLDN18.2-Positive Advanced or Metastatic Solid Tumors.Geoffrey Ku, Lin Shen, Farshid Dayyani, Jeremy Kratz, Xinjun Liang
Clinical Cancer Research. 2025-06-30
Press Mentions
Zymeworks Announces Abstract for Zanidatamab in First-Line HER2-Expressing Gastroesophageal Cancers (GEA) at the European Society for Medical Oncology (ESMO) Annual CongressSeptember 12th, 2021
Current Treatment of Esophageal Cancer and Promising Clinical Trials UnderwayMarch 13th, 2019
Immunotherapy Treatments Only Just Emerging in Esophageal, Gastric CancersJanuary 17th, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
